Industry Insights for Q1 – 2019
As we arrive in March, there is still uncertainty around what kind of Brexit we are going to face. Christina Hägglund, delivers a detailed update on all the latest news from the UK and around the world affecting regulated products and devices.
Guidance for Industry on No Deal Brexit
The European Medicines Agency (EMA) and the European Commission are providing guidance to help pharmaceutical companies responsible for both human and veterinary medicines prepare for the UK withdrawal from the EU. This aims to ensure that companies are ready to take the necessary steps to enable undisrupted supply of their medicines in the EU for the benefit of patients, based on the assumption that the UK will become a third country as of 30 March 2019. Read the latest from the EMA here.
UK – Fast Track Access to Ground Breaking Medicines
New Voluntary Scheme for Branded Medicines Pricing and Access
The aim of this new scheme, which came into effect on 01 January 2019 and replaces the Pharmaceutical Pricing Regulation Scheme, is to:
- Allow medicines to reach patients up to 6 months earlier than present.
- Save millions, by placing a 2% cap on the growth in sales of branded medicines to the National Health Service (NHS) with pharmaceutical companies repaying the NHS for spending above that limit
US – Real-World Data (RWD) and Real-World Evidence (RWE) in Clinical Drug Development
RWD and RWE is used by:
- The Food and Drug Administration (FDA) to monitor post marketing safety and adverse events.
- The healthcare community to develop guidelines and support tools for use in clinical practice.
- Industry to support clinical trial designs and observational studies aimed at generating new innovative treatment approaches.
Policies, Consultations and Guidelines
Guidance on Drug Development for Rare Diseases
Currently, the FDA and the EMA offer incentives to biopharmaceutical companies that aim to develop new orphan drugs. Ethical and regulatory standards for clinical trials of rare diseases are the same as for other trials, but the regulatory agencies are now trying to provide the flexibility needed to facilitate more efficient and successful orphan drug development programmes. Read more here.
New Rules for Certain Medical Devices
EMA Revises Guidance on the Implementation of Policy 0070
In November 2018, the EMA issued revision 4 of the guidance on its clinical data publication policy (Policy 0070). It clarifies the requirements to withdraw an application if it has been/will be resubmitted. The EMA has temporarily suspended the publication of clinical data until further notice, following the implementation of the third phase of its business continuity plan prior to its move to The Netherlands.
EMA Launches Consultation on Regulatory Science 2025
The EMA has issued its draft ‘Regulatory Science to 2025’ strategy for a 6-month public consultation. The draft strategy outlines EMA’s plans for advancing engagement with regulatory science over the next 5–10 years.
Updated Guidance on Reference Safety Information (RSI)
One of the most common grounds for non-acceptance of clinical trial applications is the lack of acceptable RSI in the Investigator’s Brochure or Summary of Product Characteristics. The Clinical Trial Facilitation Group (CTFG) has developed recommendations relating to RSI. Find out more and read the recommendations here.
Advances in New Scientific Framework for Oncology Drug Development
The FDA has issued new guidance on selecting suitable endpoints for oncology clinical trials and includes new resources, references and examples of prior regulatory approvals. It clarifies how oncology endpoints can support traditional or accelerated approval.
New ICH Reflection Paper
Historically, most of ICH’s efforts have been directed towards harmonising activities for novel drugs. ICH has however now issued a short Reflection Paper outlining an approach to enhancing the guidelines in order to support harmonisation of scientific and technical standards for generic drugs.
US and Australian Agencies Focus on Patient Access to Generic Drugs
The current regulatory framework for generic drugs places unnecessarily high burden on organisations seeking marketing authorisations. Generic drugs may however increase competition and moderate the price of prescription medicines, leading to better medicines access for a broader population of patients.
- FDA Competitive Generic Therapies Guidance for Industry
- Australian Government Consultation: Reforms to the generic medicine market authorisation process
GCP, GMP and GPVP inspections
The Medicines and Healthcare products Regulatory Agency (MHRA) Inspectorate Blog
The MHRA has used two case studies from inspections where critical and major findings were identified to highlight the importance of Sponsor oversight in the conduct of clinical trials. Read the blog here.
Inspections – EU and US Mutual Recognition
In recent months, Belgium, Denmark, Finland, Latvia, Estonia Poland and Slovenia have been added to the mutual recognition agreement between the US and EU, confirming that these countries perform Good Manufacturing Practice (GMP) inspections at a level equivalent to that in the USA.
Switzerland’s regulatory agency has begun to input information on Swiss GMP inspections into the EU’s EudraGMDP database as part of a mutual recognition agreement. Paper GMP certificates issued by EU or Swiss authorities may now be substituted with a downloadable EudraGMDP file.
- Five additional countries to benefit from EU-US mutual recognition agreement for inspections
- EU and Switzerland to improve information-sharing on good manufacturing practice through use of the EudraGMDP database